U.S. Markets open in 7 hrs 45 mins

Cardinal Health (CAH) Beats On Q3 Earnings & Revenues - Tale of the Tape

Zacks Equity Research

Cardinal Health Inc. (CAH) is a healthcare services company engaged in providing pharmaceutical and medical products and services in the United States and internationally. The company mainly operates in two segments, Pharmaceutical and Medical.

 

Currently, Cardinal Health has a Zacks Rank #3 (Hold) but that could change following its third-quarter fiscal 2015 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:

 

Earnings: Cardinal Health’s EPS surged 18% on a year-over-year basis to $1.19. It also managed to outpace the Zacks Consensus Estimate of $1.16.

 

Revenues: Revenues in the quarter increased 18% on a year-over-year basis to $25.4 billion. It also managed to beat the Zacks Consensus Estimate of $24.3 billion.

 

Key Stats: Pharmaceutical revenues surged 20% to $22.6 billion while revenues from Medical segment increased 4% to $2.8 billion in the quarter.

 

Major Factors: Last month, Cardinal Health announced it is looking forward to acquire Johnson & Johnson's Cordis business, a leading global manufacturer of cardiology and endovascular devices. This is expected to advance Cardinal Health's offering of interventional cardiology and endovascular solutions for integrated health systems and their patients.

 

Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.

 

Check back later for our full write up on this Cardinal Health earnings report later!

 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
CARDINAL HEALTH (CAH): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research